Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2025 | $67.00 | Underweight → Equal Weight | Wells Fargo |
| 8/28/2024 | $120.00 | Underweight | Wells Fargo |
| 1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
SCHEDULE 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
Wells Fargo upgraded Mesa Laboratories from Underweight to Equal Weight and set a new price target of $67.00
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
LAKEWOOD, Colo., Dec. 03, 2025 (GLOBE NEWSWIRE) -- - Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern Time (ET) on Tuesday, February 3, 2026. About Mesa LaboratoriesMesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa Laboratories ContactsGary Owen
LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences: Raymond James Napa Valley Small Cap SymposiumFormat: 1x1 Meetings Date: Monday, November 17, 2025Jefferies London Healthcare Conference Format: Fireside chatDate: Thursday, November 20, 2025Time: 12:00 p.m. GMTWebcast: Click Here 8th Annual Evercore Healthcare ConferenceFormat: Fireside chat Date: Wednesday, December 3, 2025Time: 2:10 p.m. ET The Jefferies London Healthcare Conference fireside chat will be accessible via live webcast here, and a replay will be available on th
LAKEWOOD, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q26") ended September 30, 2025 (amounts in thousands). Financial Summary – 2Q26 versus the same year ago period Revenues increased 5.0%Non-GAAP core organic revenues1 growth was 3.7%Operating income increased 34.7% to $4,724 Non-GAAP adjusted operating income ("AOI") excluding unusual items2 increased 6.1% and was 25.1% as a percentage of revenues We operate a diversified business across four divisions: Ster
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us", or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the "Board"), effective January 5, 2024. Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: "We are pleased to welcome Mark to Mesa's Board. Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics. We believe Mark's insights will be pivotal to Mesa
LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or the "Company") today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors ("Board"), effective November 3, 2022. Mr. Ladiwala assumes this newly re-created role as an expansion of his current responsibilities on the Board, on which he has served since October 2021. Mr. Ladiwala was selected for this important role due to the thoughtful leadership and contributions he has made to the Board as well as the exceptional breadth of his professional experience. Mr. Ladiwala said, "I am delighted to accept this leadership role on Mes
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, inc
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p